| Bioactivity | Koshidacin B is an antiplasmodial cyclic tetrapeptide with antiplasmodial activity against P. falciparum FCR3 and K1 strain with IC50 values of 0.89 and 0.83 μM, respectively. Koshidacin B suppresses malaria parasites in vivo, it can be used for the research of parasites infection[1]. |
| Target | IC50: 0.89 μM (P. falciparum FCR3 strain), 0.83 μM (P. falciparum K1 strain), 14.7 μM (human MRC-5 cells) |
| Invitro | Koshidacin B (72 h) shows antiplasmodial activity against chloroquine-sensitive P. falciparum FCR3 strain and chloroquine-resistant P. falciparum K1 strain with IC50 values of 0.89 and 0.83 μM, respectively[1].Koshidacin B (7 d) shows cytotoxicity against human MRC-5 cells with an IC50 value of 14.7 μM[1]. |
| In Vivo | Koshidacin B (30 mg/kg; i.p.; once daily for 4 d) shows vivo antiplasmodial effects[1]. Animal Model: |
| Name | Koshidacin B |
| Formula | C28H40N4O7 |
| Molar Mass | 544.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Watanabe Y, et al. Koshidacins A and B, Antiplasmodial Cyclic Tetrapeptides from the Okinawan Fungus Pochonia boninensis FKR-0564. J Nat Prod. 2022 Oct 25. |